Committee deadlocks on bill restricting access contractors' utilization controls; concerns about scope and cost
Loading...
Summary
Lawmakers failed to advance HB2725 after stakeholders warned section B could be read so broadly it would remove prior authorization and step-therapy controls for many non-opioid drug classes, potentially creating large fiscal impacts; the amendment preserved reporting and sunset but the committee vote was 6–6 and the bill failed.
House Bill 2,725, as amended, would have restricted some utilization controls applied by access contractors and added reporting requirements on opioid and non-opioid prescribing. Sponsor staff explained the amendment removes a prohibition on therapeutic substitution but adds a reporting requirement and a two-year sunset.
Industry witnesses told the committee the language in section B is ambiguous and could apply to all non-opioid drugs — not just non-opioid pain therapies — which would remove prior-authorization guards for high-cost drug classes. Steve Berg, legislative specialist for Access, said the provision “does not specify that this is the drug class being targeted” and warned of potentially large fiscal impacts. Beth Koehler of the Arizona Association of Health Plans gave concrete examples, including end-of-life and cancer pain cases where clinicians may appropriately access opioids without step therapy; she said the bill’s wording could unintentionally open many non-opioid drugs to unrestricted use and drive program costs up.
Committee debate centered on whether the amendment adequately preserved the Pharmacy & Therapeutics (P&T) committee’s role in clinical review. Industry representatives said the amendment was silent on the P&T process; bill proponents said they would accept clarifying amendments but the committee failed to advance the measure. The final roll call was effectively tied (6 ayes, 6 nays), and the bill did not receive a due-pass recommendation.
Because lawmakers did not advance HB2725, its reporting requirements and the two-year sunset will not take effect unless reintroduced or amended and passed in a subsequent hearing.
